Dima Kuzmin

Chairman of the Board

2025

Managing Partner

2014

72 investments in advanced therapies (and counting) across private and public markets. Committed to curing chronic diseases through advanced therapies.

Assistant Professor Adjunct of Medicine

2021

Pre-clinical and clinical trial design, ethics of access and reimbursement for one-shot curative therapies

Kauffman Fellow - Graduated

2023

Kauffman Fellow - Class 26

2021 - 2023

Kauffman Fellowship Program (Class 26): The Kauffman Fellowship is a two-year executive education program that identifies and develops global leaders in VC while providing a structured curriculum, peer learning, executive coaching, and networking — all with a focus on giving back and one's responsibility as a leader in venture capital. With 700+ Fellows across 50+ countries, Kauffman Fellows is the largest network of VCs and innovation leaders in the world. Each year, the organization adds a new cohort of 60 accomplished Fellows who attend this two-year program part-time, while they are investing full time.

Chairman of the Board

2023

Board Member

2021

Ray Therapeutics is developing novel optogenetics gene therapies for patients with blinding diseases. The company is developing its lead candidate Ray-001 in retinitis pigmentosa, a degenerative retinal disease with significant unmet medical need. The company’s mission is to use optogenetics to restore vision, agnostic of genetic mutation for patients with inherited retinal diseases.

Chairman of the Board

2022

Hornet Therapeutics is a biotech company focused on developing treatments to address EBV-driven pathologies. Read our launch paper in Science here: https://www.science.org/doi/10.1126/science.adk4898

Board Member

2021

Headquartered in Greater Philadelphia, Code Bio is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases.

Chairman of the Board

2024 - 2025

Board Member

2020 - 2024

Araris Biotech AG is pioneering a novel linker technology for antibody-drug conjugates (ADCs.) This linker platform enables the attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering. Acquired by Taiho Pharmaceutical in March 2025.

Board Member

2020 - 2022

Based in New York City, Redpin Therapeutics is a privately-held, preclinical stage gene therapy company developing a proprietary chemogenetics platform for targeted cell therapies to address currently intractable diseases of the central nervous system. Acquired by Kriya in November 2022.